Future research directions for the treatment of AML.
Karp
Judith
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D035843:Biomedical Research / Q000639:trends*; D002227:Carbazoles / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005047:Etoposide / Q000627:therapeutic use; D005419:Flavonoids / Q000627:therapeutic use; D005663:Furans; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008942:Mitoxantrone / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019772:Topotecan / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002227:Carbazoles; D004791:Enzyme Inhibitors; D005419:Flavonoids; D005663:Furans; D010880:Piperidines; D015363:Quinolones; D003561:Cytarabine; C077990:alvocidib; D014212:Tretinoin; D005047:Etoposide; D000077209:Decitabine; D019772:Topotecan; D016190:Carboplatin; D008942:Mitoxantrone; C119379:lestaurtinib; D019311:Staurosporine; C059539:midostaurin; D001374:Azacitidine; C402769:tipifarnib; D003630:Daunorubicin